Introduction {#s1}
============

A variety of metabolic insults can generate DNA lesions in mammalian cells, which, if incorrectly repaired, can lead to somatic mutations and cell transformation ([@bib78]). If unrepaired, such lesions can accumulate and constantly activate the DNA damage response (DDR), a unique feature and mechanism of senescence ([@bib27]; [@bib74]). Ataxia telangiectasia mutated (ATM), a serine/threonine protein kinase, is one of the key regulators of DDR ([@bib25]). Upon DNA damage, self-activated ATM phosphorylates downstream transducers and effectors, promoting DNA repair ([@bib4]; [@bib58]). H2AX is a well-documented phosphorylation target of ATM; phosphorylated H2AX at S139 (γH2AX) is widely recognized as a hallmark of DNA damage ([@bib10]). Accompanied by decline in DNA repair function, γH2AX-enriched DNA damage foci accumulate in senescent cells and in tissues from aged animals ([@bib52]), supporting causal links between defective DDR and aging. In human fibroblasts, a dramatic decline of homologous recombination (HR) efficiency, attributable to defective recruitment of Rad51, has been observed ([@bib43]). Similar defects in HR also have been observed in Hutchinson-Gilford progeria syndrome (HGPS), which is predominantly caused by a *LMNA* C1024T mutation ([@bib44]).

In addition to DNA damage accumulation, inherited loss-of-function mutations in essential components of DNA repair machinery accelerate aging in humans and mice ([@bib30]). Patients suffering from ataxia telangiectasia (A-T) develop prominent aging features in their second decades ([@bib9]; [@bib69]). Werner syndrome, Bloom's syndrome and Rothmund-Thomson syndrome are all progeria syndromes caused by mutations of genes that directly regulate DNA repair ([@bib5]; [@bib12]; [@bib40]; [@bib42]). Homozygous disruption of *Atm* in mice causes many premature aging features of A-T, such as growth retardation, infertility, neurodegeneration, immunodeficiency and cancer predisposition ([@bib7]). Mouse models deficient in DNA repair factors, including DNA-PKcs, Ku70, Ku80, DNA ligase IV, Artemis or Ercc1 etc., phenocopy premature aging features ([@bib28]; [@bib31]), supporting the suggestion that defects in DNA repair accelerate aging. However, whether and how robust DNA repair machinery promotes longevity is poorly understood.

Metabolic disturbance is another antagonistic hallmark of aging ([@bib48]). Although DNA repair deficiency is implicated in aging and age-related diseases including metabolic disorders ([@bib49]; [@bib70]), the mechanistic link between decreased DNA repair machinery and metabolic reprogramming during aging is poorly understood. Notably, in response to oxidative stress, ATM phosphorylates Hsp27, shifting glucose metabolism from glycolysis to the pentose phosphate pathway (PPP) ([@bib13]; [@bib39]). Inactivating ATM enhances glucose and glutamine consumption by inhibiting P53 and upregulating c-MYC ([@bib1]). However, the role of ATM in age-onset metabolic disturbances is as yet unclear.

Here, we identified a progressive decline in ATM-centered DNA repair machinery during aging, along with shunted glucose metabolism to glycolysis. DNA damage-free activation of ATM by chloroquine (CQ) promotes DNA damage clearance, rescues age-related metabolic shift, and alleviates cellular senescence. Mechanistically, ATM phosphorylates and stabilizes pro-longevity protein SIRT6. Extra copies of *Sirt6* attenuate metabolic abnormality and extend lifespan in *Atm-/-* mice. Importantly, long-term treatment of CQ restores metabolic reprogramming and extends the lifespan of nematodes and a progeria mouse model.

Results {#s2}
=======

ATM activation alleviates replicative senescence {#s2-1}
------------------------------------------------

In searching for genes/pathways that drive senescence, we employed human primary endothelial cells, which underwent replicative senescence at passage 21, with increased p21 expression and β-galactosidase activity ([Figure 1---figure supplement 1a--b](#fig1s1){ref-type="fig"}). By RNAseq analysis, a gradual decline of ATM-centered DNA repair machinery was identified ([Figure 1---figure supplement 1c--e](#fig1s1){ref-type="fig"}). Western blotting analysis confirmed progressively downregulated protein levels of ATM and its downstream target NBS1 and RAP80 in senescent human skin fibroblasts (HSFs) ([Figure 1a](#fig1){ref-type="fig"}). Mouse embryonic fibroblasts (MEFs) with limited growth capacity and senescent phenotypes when cultured in vitro ([@bib57]; [@bib63]; [@bib68]), and brain tissues from aged mice also showed progressive decline of ATM, NBS1, and RAP80 ([Figure 1b--c](#fig1){ref-type="fig"}). Concomitantly, upregulation of γH2AX, indicating accumulated DNA damage, and an increase in p16^Ink4a^ were observed in senescent HSFs, MEFs, and aged brain tissues ([Figure 1a--c](#fig1){ref-type="fig"}). Knocking down *ATM* via shRNA accelerated senescence in HSFs, evidenced by increased β-galactosidase activity ([Figure 1d--e](#fig1){ref-type="fig"}), enlarged morphology ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}), accumulated γH2AX ([Figure 1f](#fig1){ref-type="fig"}), and reduced cell proliferation ([Figure 1---figure supplement 2b](#fig1s2){ref-type="fig"}). These data indicate that ATM decline retards DDR and drives senescence.

![ATM activation by chloroquine alleviates senescence.\
(**a**) Immunoblots showing protein levels of ATM, NBS1, and RAP80 in human skin fibroblasts (HSFs). A gradually increased level of p16 indicates cellular senescence, while elevated γH2AX level indicates accumulated DNA damage. (**b**) Immunoblots showing protein levels of ATM, NBS1, and RAP80 in mouse embryonic fibroblasts (MEFs). (**c**) Immunoblots showing protein levels of ATM, NBS1, and RAP80 in brain tissues isolated from 3-, 10-, and 18-month-old male mice. (**d**) SA-β-Gal staining in HSFs treated with sh-*ATM* or scramble shRNA. Scale bar, 100 µm. (**e**) Quantification of SA-β-Gal-positive staining of (**d**) from five views randomly captured for each group. Data represent means ± SEM. \*\*\*p\<0.001. (**f**) Immunoblots showing increased γH2AX and unaffected LC3I/II in HSFs treated with sh-*ATM* or scramble shRNA. (**g**) Immunoblots showing protein levels of pS1981 ATM, γH2AX, and cleaved caspase-3 in HSFs treated with 10 μM of CQ for indicated time. (**h**) SA-β-Gal staining in HSFs expressing either scramble or *ATM* shRNA treated with 1 μM CQ or DMSO (12 hr). Scale bar, 100 µm. (**i**) Quantification of SA-β-Gal-positive staining of (**h**) from five views randomly captured for each group. Data represent means ± SEM. \*\*\*p\<0.001; 'N.S.' indicates no significant difference. (**j**) HSFs at passage 20 were continuously cultured with 1 μM CQ or DMSO, and cell number was calculated at each passage. Data represent means ± SEM. \*\*\*p\<0.01. (**k**) Immunoblots showing protein levels of γH2AX, p62, and LC3 in MEFs treated with 1 μM CQ or DMSO. Note that CQ had little effect on the expression levels of p62 and LC3. (**l**) MEFs at passage one were continuously cultured in 20% O~2~ with 1 μM CQ or DMSO, and cell number was determined at each passage. Data represent means ± SEM. \*\*\*p\<0.01.\
10.7554/eLife.34836.006Figure 1---source data 1.Statistical analysis for SA-β-Gal positive staining.\
10.7554/eLife.34836.007Figure 1---source data 2.Statistical analysis for EdU positive staining.](elife-34836-fig1){#fig1}

Other than DNA damage, ATM is activated by chloroquine (CQ), an antimalarial drug that modulates chromatin confirmation ([@bib4]). We confirmed that a low dose of CQ increased the level of pS1981 auto-phosphorylation of ATM but not γH2AX ([Figure 1---figure supplement 2c](#fig1s2){ref-type="fig"}). We then investigated whether activating ATM by CQ can ameliorate senescence. As shown, the CQ treatment activated ATM (pS1981), promoted clearance of DNA damage (γH2AX), and inhibited apoptosis (cleaved Casp3) in HSFs ([Figure 1g](#fig1){ref-type="fig"}). Also, the CQ treatment suppressed β-galactosidase activity, which was abrogated if *ATM* was knocked down ([Figure 1h--i](#fig1){ref-type="fig"}). Importantly, CQ treatment extended the replicative lifespan of HSFs ([Figure 1j](#fig1){ref-type="fig"}). Likewise, CQ treatment activated Atm, cleared up accumulated DNA damage, suppressed β-galactosidase activity ([Figure 1k](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2d--e](#fig1s2){ref-type="fig"}), and prolonged replicative lifespan in MEFs ([Figure 1l](#fig1){ref-type="fig"}). Although both 10 μM and 1 μM of CQ activated ATM, a dose-dependent toxicity assay showed that 1 μM is suitable for long-term treatment ([Figure 1---figure supplement 2f--g](#fig1s2){ref-type="fig"}). Of note, *ATM* KD or low dose of CQ applied in this study had little effect on basal autophagic activity ([Figure 1f,j](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2g](#fig1s2){ref-type="fig"}). Collectively, CQ activates ATM to alleviate replicative senescence.

An ATM-SIRT6 axis underlies age-associated metabolic reprogramming {#s2-2}
------------------------------------------------------------------

A-T patients lacking functional ATM display features of premature aging, accompanied by insulin resistance and glucose intolerance ([@bib6]; [@bib20]). Senescent cells exhibit impaired mitochondrial respiration, but enhanced glycolysis producing more lactate ([@bib26]; [@bib41]). As such, we wondered whether ATM decline triggers an age-associated metabolic shift. Levels of glycolytic genes *LDHB* and *PDK1* were dramatically increased in senescent MEFs and HSFs ([Figure 2a](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}), and in liver tissues from *Atm***-/-** mice ([Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}). Significantly, activating ATM via CQ suppressed senescence-associated glycolysis ([Figure 2a](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). Similarly, the inhibitory effect on glycolysis was diminished when *ATM* was depleted in HepG2 cells ([Figure 2b](#fig2){ref-type="fig"}). These data suggest a role for ATM in inhibiting glycolysis.

![ATM-SIRT6 axis regulates age-related metabolic reprogramming.\
(**a**) Quantitative RT-PCR analysis of mRNA levels of indicated glycolytic genes in different passages of MEFs with or without treatment of CQ. Data represent means ± SEM. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**b**) Quantitative RT-PCR analysis of mRNA levels of indicated glycolytic genes in Scramble (NC), si-*SIRT6* or si-*ATM* HepG2 cells incubated with or without CQ (10 μM, 6 hr). Data represent means ± SEM. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**c**) Heatmap representation of RNA-Seq data (GSE109280) showing relative changes of glycolytic genes in *Atm-/-* MEF cells. The transcript levels are qualified in reads per kilobase of exon per million mapped sequence reads (RPKM), which is a normalized measure of exonic read density. Red and green indicate up- and downregulation, respectively. (**d**) Heatmap showing relative levels of metabolites in *Atm+/+* and *Atm-/-* MEF cells of p53 null background, analyzed by LC-MS. Red and blue indicate up- and downregulation, respectively. (**e**) Immunoblots showing protein levels of H3K9ac and H3K56ac in *ATM*-deficient HepG2 cells. (**f**) Immunoblots showing levels of H3K9ac in A-T cells reconstituted with Flag-ATM. (**g**) ChIP analysis showing enrichment of H3K9ac at the promoter regions of indicated genes in *Atm+/+* and *Atm-/-* MEFs. Data represent means ± SEM of three independent experiments. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**h**) ChIP analysis showing enrichment of Sirt6 at the promoter regions of indicated genes in *Atm+/+* and *Atm-/-* MEFs. Data represent means ± SEM of six independent experiments. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**i**) Immunoblots showing protein levels of sirtuins in wild-type (WT) and *ATM* knockout (KO) HEK293 cells. (**j**) Kaplan-Meier survival of *Atm-/-* and *Atm-/-;Sirt6*-Tg male (n = 11 in each group) and female (n = 9 in each group) mice. \*\*p\<0.01. (**k**) Results of glucose tolerance tests in *Atm+/+, Atm-/-,* and *Atm-/-;Sirt6*-Tg mice. Data represent means ± SEM, n = 6. \*\*p\<0.01, \*\*\*p\<0.001. (**l**) Results of insulin tolerance tests in *Atm+/+*, *Atm-/-*, and *Atm-/-;Sirt6*-Tg mice. Data represent means ± SEM, n = 6. \*\*p\<0.01. 'ns' indicates no significant difference.\
10.7554/eLife.34836.011Figure 2---source data 1.Differently expressed mRNA profiles of Atm-/- MEF cells.\
10.7554/eLife.34836.012Figure 2---source data 2.Differentially expressed Metabolites in Atm KO MEFs.\
10.7554/eLife.34836.013Figure 2---source data 3.Differently expressed mRNA profiles of Sirt6-/- MEF cells.](elife-34836-fig2){#fig2}

To examine how ATM regulates glycolysis, we performed RNA-Seq in *Atm-/-* MEF cells, and revealed a significant upregulation of glycolytic pathways ([Figure 2c](#fig2){ref-type="fig"}, and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Specific genes were validated by q-PCR ([Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"}). As p53 is critical in glycolysis ([@bib38]; [@bib66]), we further analyzed metabolomics of *Atm-/-* and control MEFs in *p53* null background. As shown, the metabolic profile exhibited a clear shift, i.e. mitochondrial electron transport chain and intermediates of TCA cycle were reduced, while intermediates of glycolysis were elevated ([Figure 2d](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1d--e](#fig2s1){ref-type="fig"} and [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). The data suggest that *ATM* deficiency enhances anaerobic glycolysis in a p53-independent manner.

Sirt6 deacylase is able to shunt energy metabolism away from anaerobic glycolysis to the TCA cycle via H3K9ac-mediated local chromatin remodeling ([@bib67]; [@bib86]). We noted that the level of H3K9ac was enhanced in cells depleted *ATM* ([Figure 2e](#fig2){ref-type="fig"}). Re-expressed ATM in A-T cells suppressed H3K9ac level ([Figure 2f](#fig2){ref-type="fig"}). ChIP analysis showed that H3K9ac was enriched at the promoter regions of glycolytic genes in *Atm-/-* cells ([Figure 2g](#fig2){ref-type="fig"}), where the relative occupancy of SIRT6 was abolished ([Figure 2h](#fig2){ref-type="fig"}). Consistent with increased H3K9ac, SIRT6 protein level was dramatically downregulated in *Atm-/-* mouse livers, and *ATM*-deficient HepG2, U2OS and HEK293 cells ([Figure 2---figure supplement 1f--i](#fig2s1){ref-type="fig"}). In contrast, protein levels of other sirtuins were not much affected in *ATM* KO HEK293 cells ([Figure 2i](#fig2){ref-type="fig"}), and mRNA levels of all sirtuins remained unchanged ([Figure 2---figure supplement 1j](#fig2s1){ref-type="fig"}). Moreover, transcriptomic analysis and q-PCR data illustrated that *Sirt6* depletion upregulated a similar cluster of genes essential for glycolysis ([Figure 2---figure supplement 2a--b](#fig2s2){ref-type="fig"} and [Figure 2---source data 3](#fig2sdata3){ref-type="supplementary-material"}). More importantly, the hyper-activated glycolytic pathway caused by *ATM* deficiency was completely restored by ectopic *SIRT6* in HepG2 cells ([Figure 2---figure supplement 2c](#fig2s2){ref-type="fig"}). The CQ treatment upregulated SIRT6 level and reduced H3K9ac level, especially at the regulatory regions of glycolytic genes ([Figure 2---figure supplement 2d--e](#fig2s2){ref-type="fig"}). Knocking down *SIRT6* abolished the inhibitory effect of CQ on glycolysis ([Figure 2b](#fig2){ref-type="fig"}). Additionally, *ATM* depletion in HEK293 cells, HSFs, and MEFs, significantly downregulated SIRT6 protein level, with little effect on SIRT1 or SIRT7 ([Figure 2i](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2f--g](#fig2s2){ref-type="fig"}). Thus, these data suggest that ATM decline triggers an age-associated metabolic shift via SIRT6-mediated chromatin remodeling.

Other than metabolic abnormality, depleting *Sirt6* leads to premature aging features and shortened lifespan ([@bib55]), whereas extra copies of *Sirt6* promote longevity in male mice ([@bib33]). Given that Sirt6 was destabilized in *Atm* null mice, we wondered whether the *Sirt6* transgene could rescue premature aging phenotypes and shortened lifespan in *Atm*-/- mice. To this end, we generated *Sirt6* transgenic mice by microinjection, and bred them with *Atm-/-* mice. The overexpression of Sirt6 was demonstrated by western blotting ([Figure 2---figure supplement 2h](#fig2s2){ref-type="fig"}). Significantly, ectopic *Sirt6* restored the elevation of serum lactate, and extended lifespan of *Atm-/-* mice of both genders ([Figure 2j](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2i](#fig2s2){ref-type="fig"}). Importantly, *Atm-/-;Sirt6-*tg mice exhibited improved glucose tolerance and decreased insulin resistance ([Figure 2k--l](#fig2){ref-type="fig"}). Given that little difference was observed in glucose metabolism between young wild-type (WT) and *Sirt6*-transgenic mice ([@bib33]), these data suggest a contributory role of the Atm-Sirt6 axis in the age-associated metabolic reprogramming.

ATM phosphorylates and stabilizes SIRT6 {#s2-3}
---------------------------------------

Next, we examined how ATM regulates SIRT6. Significantly, overexpression of *ATM* increased SIRT6 level, but this was abolished when ATM was S1981A-mutated to block dimeric ATM dissociation ([@bib4]; [@bib8]) ([Figure 3a](#fig3){ref-type="fig"}). Moreover, in addition to CQ, hypotonic buffer (20 mM NaCl), low glucose (LG), DNA-damaging agent camptothecin (CPT), and doxorubicin (Dox) all activated ATM and concomitantly increased SIRT6 protein level ([Figure 3---figure supplement 1a--c](#fig3s1){ref-type="fig"}), which was abrogated in *ATM*-depleted cells ([Figure 3---figure supplement 1b--c](#fig3s1){ref-type="fig"}). These data implicate a direct regulation of SIRT6 stability by ATM kinase activity. To confirm this, we first performed co-immunoprecipitation (Co-IP) in cells transfected with various FLAG-sirtuins. Interestingly, ATM was predominantly associated with SIRT6 among seven sirtuins ([Figure 3b](#fig3){ref-type="fig"}). The interaction was further confirmed at both ectopic and endogenous levels ([Figure 3c](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1d](#fig3s1){ref-type="fig"}). Immunofluorescence microscopy showed co-localization of SIRT6 and ATM protein in the nucleus ([Figure 3d](#fig3){ref-type="fig"}). A domain mapping experiment indicated that the C-terminal domain was required for SIRT6 binding to ATM ([Figure 3---figure supplement 1e](#fig3s1){ref-type="fig"}). To determine whether ATM physically binds to SIRT6, 10 consecutive recombinant GST-ATM proteins were obtained and the binding to purified His-SIRT6 was analyzed. As shown ([Figure 3e](#fig3){ref-type="fig"}), His-SIRT6 bound predominantly to GST-ATM-4 (residues 770--1102) and relatively weakly to GST-ATM-1 (residues 1--250); both belong to the N-terminal HEAT repeat domain of ATM.

![ATM interacts with and phosphorylates SIRT6.\
(**a**) Immunoblots showing protein levels of SIRT6 in HEK293 cells expressing Flag-ATM or Flag-ATM S1981A. (**b**) Immunoblots showing endogenous ATM and p-S/TQ motif in anti-Flag immunoprecipitates in HEK293 cells transfected with empty vector or Flag-sirtuins. (**c**) Immunoblots showing Flag-ATM and HA-SIRT6 in anti-HA (upper) or anti-Flag (lower) immunoprecipitates in HEK293 cells transfected with indicated constructs. (**d**) Representative photos of immunofluorescence staining of SIRT6 and ATM in U2OS cells, showing co-localization in the nucleus. Scale bar, 50 µm. (**e**) GST pull-down assay showing bacterially expressed His-SIRT6 predominantly bound to GST-ATM fragment 4 (770--1102), the N-terminal HEAT-repeat of ATM. (**f**) Immunoblots showing the increased binding capacity of ATM and SIRT6 under the treatment of (10 µM) CQ for the indicated time. (**g**) Immunoblots showing ATM and p-S/TQ in anti-Flag immunoprecipitates in HEK293 cells expressing Flag-SIRT6 treated with CPT (0.4 µM) or DMSO. (**h**) Immunoblots showing level of p-S/TQ SIRT6 in HEK293 cells co-transfected with HA-SIRT6 and Flag-ATM, Flag-ATM S1981A, or empty vector. (**i**) Immunoblots showing p-S/T Q SIRT6 in WT or *ATM* KO HEK293 cells. (**j**) Immunoblots showing p-S/T Q level of SIRT6 in *ATM* WT or KO HEK293 cells treated with DMSO and KU55933 (10 or 20 µM, 2 hr). (**k**) Alignment of protein sequence of human SIRT6 and orthologues in mouse, rat, fruit fly, *Xenopus*, and *C. elegans.* A conserved S^112^ Q^113^ motif was highlighted. (**l**) Immunoblots showing p-S/T Q level of Flag-SIRT6, Flag-SIRT6 S112A, or Flag-SIRT6 S112D in HEK293 cells. (**m**) Quantitative RT-PCR analysis of mRNA levels of indicated glycolytic genes in sh-*SIRT6* HepG2 cells re-expressing SIRT6, SIRT6 S112A, or 112D mutation. Data represent means ± SEM. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. 'ns' indicates no significant difference. (**n**) Immunoblots showing SIRT6 protein level in total cell extract (TCE) and chromatin-enriched fractions (P2). Densitometry analysis was performed to determine the relative ratio of SIRT6/H2B within chromatin fractions.](elife-34836-fig3){#fig3}

We next examined whether ATM phosphorylates SIRT6. Firstly, we found that CQ or CPT treatment significantly enhanced the binding of SIRT6 to ATM ([Figure 3f](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1f](#fig3s1){ref-type="fig"}), whereas the S1981A mutant blocked such association ([Figure 3---figure supplement 1g](#fig3s1){ref-type="fig"}). ATM preferentially phosphorylates the S/T-Q motif. In the presence of CPT, an increased p-S/TQ level of SIRT6 was identified ([Figure 3g](#fig3){ref-type="fig"}). Of note, lambda protein phosphatase (λPP) diminished the p-S/TQ level of SIRT6 ([Figure 3---figure supplement 1h](#fig3s1){ref-type="fig"}). Likewise, the p-S/TQ level of SIRT6 was elevated in cells treated with low glucose, which activates ATM by ROS generation ([@bib3]; [@bib64]) ([Figure 3---figure supplement 1i](#fig3s1){ref-type="fig"}). Moreover, ectopic ATM significantly increased the p-S/TQ level of SIRT6, but this was abolished in the case of S1981A mutant ([Figure 3h](#fig3){ref-type="fig"}). Consistently, a pronounced reduction of p-S/TQ level of SIRT6 was observed in cells lacking *ATM* or treated with KU55933, a selective and specific ATM kinase inhibitor ([@bib8]; [@bib29]) ([Figure 3i--j](#fig3){ref-type="fig"}). The decrease in p-S/TQ level was primarily attributable to loss of *ATM*, as it was restored by ectopic FLAG-ATM in a dose-dependent manner ([Figure 3---figure supplement 1j](#fig3s1){ref-type="fig"}). Indeed, SIRT6 has one evolutionarily conserved S^112^Q^113^ motif ([Figure 3k](#fig3){ref-type="fig"}). We therefore constructed S112A and S112D mutants, which resemble hypo- and hyper-phosphorylated SIRT6 respectively. As shown, these mutations almost abolished the pS/T-Q level of FLAG-SIRT6 ([Figure 3l](#fig3){ref-type="fig"}). The in vitro kinase assay showed that ATM could phosphorylate GST-SIRT6, but not S112A ([Figure 3---figure supplement 1k](#fig3s1){ref-type="fig"}). Furthermore, compared with SIRT6 S112A, ectopic S112D exhibited a much higher inhibitory effect on glycolytic gene expression in sh-*SIRT6* HepG2 cells ([Figure 3m](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1l](#fig3s1){ref-type="fig"}), and enhanced chromatin association of SIRT6 ([Figure 3n](#fig3){ref-type="fig"}). Collectively, the data suggest that ATM directly phosphorylates SIRT6 at Serine 112.

We next examined whether ATM is involved in regulating SIRT6 protein stability. Notably, compared with WT or vehicle control, the degradation rate of ectopic and endogenous SIRT6 was largely increased in *ATM* KO HEK293 cells, *Atm***-/-** MEFs, and cells incubated with KU55933 in the presence of cycloheximide (CHX) ([Figure 4a--b](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1a--c](#fig4s1){ref-type="fig"}). Recently, MDM2 was demonstrated to ubiquitinate SIRT6 and promote its proteasomal degradation ([@bib76]). We therefore examined the polyubiquitination level of SIRT6. As shown, the ubiquitination level of FLAG-SIRT6 in *ATM* KO cells was significantly elevated compared with WT ([Figure 4---figure supplement 1d](#fig4s1){ref-type="fig"}). While S112A mutant markedly enhanced the polyubiquitination level of SIRT6, S112D had little effect ([Figure 4---figure supplement 1e](#fig4s1){ref-type="fig"}). Moreover, S112A accelerated SIRT6 degradation, whereas S112D retarded it ([Figure 4c--d](#fig4){ref-type="fig"}), indicating that the Ser112 phosphorylation by ATM regulates SIRT6 ubiquitination and thus protein stability. Indeed, ectopic MDM2 enhanced the polyubiquitination level of FLAG-SIRT6 ([Figure 4---figure supplement 1f](#fig4s1){ref-type="fig"}). In the case of *ATM* depleted or SIRT6 S112A mutant, the binding capacity of SIRT6 to MDM2 was enhanced ([Figure 4e](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1g](#fig4s1){ref-type="fig"}). In searching for key residues that are polyubiquitinated by MDM2, we identified two clusters of lysine residues, i.e. K143/145 and K346/349, which are conserved across species. We then generated KR mutations of these residues, and found that K346/349R remarkably reduced the polyubiquitination level of SIRT6 ([Figure 4---figure supplement 1h](#fig4s1){ref-type="fig"}). Individual KR mutation showed that K346R significantly blocked MDM2-mediated ubiquitination and degradation of SIRT6, whereas K349R hardly affected it ([Figure 4f--g](#fig4){ref-type="fig"}). More importantly, K346R restored the increased ubiquitination and accelerated protein degradation of SIRT6 S112A ([Figure 4---figure supplement 1i--j](#fig4s1){ref-type="fig"}). Collectively, these data indicate that K346 is subject to MDM2-mediated ubiquitination, which is inhibited by ATM-mediated S112 phosphorylation.

![ATM prevents ubiquitination and degradation of SIRT6.\
(**a**) Immunoblots showing protein levels of Flag-SIRT6 in WT and *ATM* KO HEK293 cells treated with CHX (50 µg/ml) for indicated periods of time. (**b**) Quantification of protein levels in (**a**) by ImageJ. Data represent means ± SEM of three independent experiments. \*\*p\<0.01. (**c**) Immunoblots showing protein levels of Flag-SIRT6, S112A, and S112D in the presence of CHX (50 μg/ml) for indicated periods of time. (**d**) Quantification of protein levels in (**c**) by ImageJ. Data represent means ± SEM of three independent experiments. \*\*\*p\<0.001. (**e**) Immunoblots showing increased binding capacity between SIRT6 and MDM2 in *ATM* KO HEK293 cells. (**f**) Immunoblots showing ubiquitination of Flag-SIRT6, K346R, K349R, and K346/349R (2KR) in HEK293 cells. Note that 2KR and K346R abrogated the ubiquitination of Flag-SIRT6. (**g, h**) Upper, immunoblots showing protein levels of Flag-SIRT6, K346R, and K349R in the presence of CHX (50 μg/ml) for indicated periods of time. Lower, quantification of protein levels by ImageJ. Data represent means ± SEM of three independent experiments. \*\*\*p\<0.001.](elife-34836-fig4){#fig4}

Activating ATM via CQ promotes longevity {#s2-4}
----------------------------------------

The cellular data suggest a pro-longevity function of ATM. We then tested it at organismal level. We employed *Caenorhabditis elegans,* which have a short lifespan of approximate 30 days. Nematodes deficient for *atm-1*, an orthologue of mammalian *ATM*, and WTs were exposed to various doses of CQ (see Materials and methods). Significantly, the period treatment with CQ (1.0 µM) extended the median lifespan (\~14%) of *C. elegans* ([Figure 5a](#fig5){ref-type="fig"}). The lifespan-extending effect was abolished in *atm-1* KO ([Figure 5b](#fig5){ref-type="fig"}) or in SIRT6 homolog *sir-2.4* KD nematodes ([Figure 5---figure supplement 1a--b](#fig5s1){ref-type="fig"}). The data suggest that CQ promotes longevity in an ATM- and SIRT6- dependent manner. We further examined the beneficial effect of CQ in a HGPS model, i.e. *Zmpste24***-/-** mice, which has a shortened lifespan of 4--6 months ([@bib59]) and impaired ATM-mediated DNA repair signaling ([@bib45]). We found that the level of Atm was dramatically reduced in *Zmpste24***-/-** MEFs and tissues ([Figure 5c](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1c](#fig5s1){ref-type="fig"}). Significantly, CQ treatment activated Atm, stabilized Sirt6, decreased the accumulated DNA damage, inhibited glycolysis, and alleviated senescence in *Zmpste24***-/-** cells ([Figure 5d--e](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1d--e](#fig5s1){ref-type="fig"}). The CQ treatment also delayed body weight decline, increased running endurance, and prolonged lifespan in *Zmpste24***-/-** mice ([Figure 5f--h](#fig5){ref-type="fig"}), but had no significant effect on the lifespan of *Atm-/-* mice ([Figure 5---figure supplement 1f](#fig5s1){ref-type="fig"}).

![CQ extends lifespan in an ATM- dependent manner.\
(**a**) Survival analysis of *C. elegans* treated with the indicated dosage of CQ. \*\*p\<0.01. NS indicates no significant difference. (**b**) Survival analysis of wild-type and *atm-1* null *C. elegans* cultured in medium with or without 1 µM CQ. (**c**) Immunoblots showing protein levels of Atm and γH2AX in brain tissues of *Zmpste24+/+* (2 months), *Zmpste24-/-* (2 months), and *Zmpste24-/-* (4 months) mice. (**d**) Representative images showing SA-β-Gal staining in *Zmpste24-/-* MEFs with or without CQ treatment. Scale bar, 100 µm. (**e**) Quantitative RT-PCR analysis of mRNA levels of *p16^Ink4a^* and indicated glycolytic genes in liver tissues of *Zmpste24+/+*, saline-treated, and CQ-treated *Zmpste24-/-* mice. Mice were treated for 8 weeks with two weekly intraperitoneal injections of CQ at 3.5 mg/kg. Data represent means ± SEM. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. (**f**) Maximum running duration in saline- and CQ-treated *Zmpste24-/-* mice. Data represent means ± SEM. \*\*\*p\<0.001. (**g**) Body weight of saline- and CQ-treated male *Zmpste24-/-* mice. Data represent means ± SEM. \*\*p\<0.01. (**h**) Kaplan-Meier survival curves of saline-treated (n = 10) and CQ-treated (n = 8) *Zmpste24-/-* mice. \*\*\*p\<0.001. (**i**) Quantitative RT-PCR analysis of mRNA levels of indicated glycolytic genes in the liver tissues of 4-month-old, saline-treated 12-month-old (n = 3), and CQ-treated 20-month-old (n = 3) mice. Data represent means ± SEM. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.\
10.7554/eLife.34836.021Figure 5---source data 1.Lifespan analysis of chloroquine\'s effect on nematodes.\
10.7554/eLife.34836.022Figure 5---source data 2.Lifespan analysis of chloroquine\'s effect on mice.](elife-34836-fig5){#fig5}

Physiologically aged mice frequently develop aging-associated metabolic disorders, with high glucose and lactate ([@bib32]). Given that ATM declines with age, and activation of ATM by CQ inhibits glycolysis in senescent cells and *Zmpste24**-/-*** mice, we intraperitoneally administrated 12-month-old 'old' male mice with low-dose CQ (3.5 mg/kg) twice a week. Remarkably, compared with the saline-treated group, CQ treatment inhibited glycolysis, lowered serum lactate level, and attenuated body weight decline ([Figure 5i](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1g--h](#fig5s1){ref-type="fig"}), implicating potential benefits of CQ in physiologically aged mice. Generally, these data demonstrate a lifespan-extending benefit of ATM activation by CQ.

Discussion {#s3}
==========

DNA damage accumulates with age, and defective DDR and DNA repair accelerates aging. However, whether boosting DNA repair machinery promotes healthiness and longevity is still unknown. DNA damage stimulates DDR, but if persistent, it instead leads to senescence. Therefore, if enhancing DDR efficacy possibly promotes longevity, it must be DNA damage free. The antimalarial drug CQ can intercalate into the internucleosomal regions of chromatin, unwind DNA helical twist, and thus activate ATM without causing any DNA damage ([@bib4]; [@bib36]). We demonstrate that long-term treatment with CQ activates ATM, improves DNA repair, restores age-related metabolic shift, alleviates cellular senescence, and extends lifespan of nematodes and *Zmpste24* null mice. Mechanistically, ATM phosphorylates the longevity gene SIRT6 ([@bib75]), and prevents MDM2-mediated ubiquitination and proteasomal degradation of SIRT6. To our knowledge, this is the first study to establish direct causal links between robust DNA repair machinery and longevity. In support of this notion, DNA repair efficacy has been shown to be enhanced in long-lived naked mole rat ([@bib51]), and human longevity has been shown to be associated with single nucleotide polymorphisms (SNPs) in DNA repair genes/pathways ([@bib15]; [@bib72]). Interestingly, the heterozygous rather than homozygous status of a SNP, albeit both enhance the transcription of *ATM*, is associated with longevity in Chinese and Italian populations ([@bib11]; [@bib60]). Therefore, in future study, it would be worthwhile evaluating whether *Atm* can promote longevity in model organisms, and, if so, how many extra copies are required.

Accumulation of DNA damage and metabolic disturbance are common denominators of aging ([@bib48]; [@bib54]). Metabolic reprogramming from the TCA cycle to glycolysis is prominent in both physiological and pathological aging ([@bib22]; [@bib70]). Why senescent cells become glycolytic is poorly understood. The crosstalk between cellular metabolism and DDR is not well elucidated. Upon genotoxic stress, ATM represses the rapamycin-sensitive mammalian target of the rapamycin (mTORC1) pathway ([@bib2]), but activates the pentose phosphate pathway (PPP) ([@bib13]), suggesting that cell metabolism may be key downstream of DDR signaling. Moreover, it is recognized that deficiency in DNA repair machinery such as ATM, WRN, and Ercc1, accelerates aging and causes severe metabolic disorders ([@bib23]; [@bib80]). In this study, we showed that boosting ATM activity using a low dose of CQ enhances genomic stability, attenuates age-onset metabolic reprogramming, alleviates senescence, and extends lifespan in mice. The data demonstrate for the first time that enhanced DNA repair machinery (ATM-SIRT6 axis) promotes longevity. Considering that ATM and SIRT6 function not only in maintenance of genome integrity but also as homeostatic protein modifiers, the pro-longevity role of ATM is most likely benefited from enhanced DNA repair and metabolic homeostasis, but it is difficult to determine which is more important.

Recently, Bohr's group identified that increased consumption of NAD^+^ by an early DDR factor poly (ADP-ribose) polymerase (PARP1), owing to accumulated DNA damage, accelerated aging in *Atm* mutant mice ([@bib21]). NAD^+^ serves as a cofactor of sirtuins, including SIRT1 and SIRT6. Therefore, this work establishes a linear causal link between deficient DDR, DNA damage accumulation, consumption of NAD^+^, decline in sirtuin activity, and aging. Moreover, administration of nicotinamide mononucleotide or nicotinamide riboside ameliorates age-related function decline and extends lifespan in mice ([@bib53]; [@bib84]). Here, we found that ATM decline during aging causes DNA damage accumulation and enhances glycolysis, both of which consume most of the NAD^+^, providing an explanation for the low NAD^+^ level in *Atm-/-* mice and physiologically aged mice.

Closely resembling normal aging, HGPS has attracted numerous efforts in understanding of molecular mechanisms and developing therapeutic strategies ([@bib14]; [@bib18]). We and others have found that HGPS and *Zmpste24* null cells undergo premature senescence because of defective chromatin remodeling ([@bib24]; [@bib37]; [@bib45]; [@bib46]), delayed DDR, and impaired DNA repair ([@bib44]; [@bib46]; [@bib77]). Specifically, Atm-Kap-1 signaling is compromised ([@bib45]), and SIRT6 protein level and deacetylase activity are reduced in progeria cells ([@bib17]; [@bib24]). Here we showed that Atm is significantly downregulated, which explains the reduced SIRT6, delayed DDR, and metabolic shift in progeria cells and mice. It would be interesting to investigate whether ectopic *Atm* or *Sirt6* could rescue progeroid features in these mice. Nevertheless, the activation of ATM via CQ remarkably improves glucose homeostasis, DNA damage clearance, and running endurance, and extends lifespan in progeria mice. It would be worthwhile evaluating the pro-longevity benefits of CQ in physiological aging.

CQ is an FDA-approved and clinically used medicine for treatment of malaria (2015). Via activation of ATM, long-term treatment of CQ protects against atherosclerosis, improves insulin sensitivity, and rescues glucose tolerance in type 2 diabetes (T2D) ([@bib16]; [@bib62]; [@bib65]). The lysosomotropic property of CQ also makes it a potent inhibitor of autophagy ([@bib83]). The application of CQ for antimalarial treatment (500 mg/week, maximum 0.8 µM in plasma) and for cancer therapy (100--500 mg/day) ([@bib35]) is attributed to its inhibitory action on autophagy. Of note, CQ also the attenuates inflammatory response by inhibiting autophagy ([@bib73]; [@bib79]; [@bib82]), requiring a high dosage of 50 mg/kg for mice. In the current study, we used a low dose of CQ to activate ATM, i.e. 1--10 μM for cell line and 3.5 mg/kg twice a week for mice ([@bib65]). The results showed that at such low doses, CQ has no toxicity and little effect on basal autophagic activity. Moreover, a low dose of CQ prolongs lifespan in progeroid mice, but exhibits little effect on *Atm* KO background, supporting an ATM-dependent pro-longevity function of CQ. Unfortunately, we could not test the CQ effect in *Sirt6-/-* mice with only 1-month lifespan ([@bib56]). Here, we addressed the pro-longevity benefits of CQ-activated ATM, most likely attributable to improved DNA repair and glucose metabolism. Given that ATM also displays anti-inflammatory function ([@bib19]; [@bib71]), we could not rule out an anti-inflammatory effect in lifespan extension observed in CQ-treated mice.

In conclusion, our data establish direct causal links between robust DNA repair machinery and longevity. In line with DNA damage theory of aging, we propose that DNA damage activates DDR; however, its constant activation causes senescence; defective ATM-SIRT6 axis underlies premature aging, exemplified by HGPS and A-T mouse models, which are rescued by treatment of CQ and *Sirt6* transgene, respectively; in physiological aging, DNA damage-free activation of ATM by CQ stabilizes SIRT6, thus promoting longevity in nematodes and most likely also in mice ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Our findings provide a novel therapeutic strategy for HGPS, and could facilitate clinical trials of CQ as an effective treatment for age-related diseases.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\           Designation                                   Source or reference                                                              Identifiers                                                                                 Additional\
  or resource                                                                                                                                                                                                                                                  information
  --------------------------------- --------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  Gene (human)                      ATM                                           National Center for Biotechnology Information                                    Gene ID: 472                                                                                

  Gene (mouse)                      Atm                                           National Center for Biotechnology Information                                    Gene ID: 11920                                                                              

  Gene (*Caenorhabditis elegans*)   atm-1                                         National Center for Biotechnology Information                                    Gene ID: 3565793                                                                            

  Gene (human)                      SIRT6                                         National Center for Biotechnology Information                                    Gene ID: 51548                                                                              

  Gene (mouse)                      Sirt6                                         National Center for Biotechnology Information                                    Gene ID: 50721                                                                              

  Gene (*Caenorhabditis elegans*)   sir-2.4                                       National Center for Biotechnology Information                                    Gene ID: 182284                                                                             

  Gene (mouse)                      Zmpste24                                      National Center for Biotechnology Information                                    Gene ID: 230709                                                                             

  Gene (mouse)                      p53                                           National Center for Biotechnology Information                                    Gene ID: 230710                                                                             

  Cell line (human)                 HEK293                                        ATCC                                                                             Catalog number: ATCC CRL-1573; RRID:[CVCL_0042](https://scicrunch.org/resolver/CVCL_0042)   

  Cell line (human)                 HepG2                                         ATCC                                                                             Catalog number: ATCC HB-8065; RRID:[CVCL_0027](https://scicrunch.org/resolver/CVCL_0027)    

  Cell line (human)                 U2OS                                          ATCC                                                                             Catalog number: ATCC HTB-96; RRID:[CVCL_0042](https://scicrunch.org/resolver/CVCL_0042)     

  Cell line (mouse)                 *Atm-/-; p53-/-* MEF                          from Dr. Yosef Shiloh (Tel Aviv University, Israel)                                                                                                                          

  Cell line (mouse)                 *Sirt6-/- MEF*                                from Dr. Raul Mostoslavsky (Massachusetts General Hospital Cancer center, USA)                                                                                               

  Antibody                          ATM                                           Abcam (Cambridge, UK)                                                            Cat\# ab78; RRID:[AB_306089](https://scicrunch.org/resolver/AB_306089)                      Applications: WB;Immunofluorescence

  Antibody                          SIRT6                                         Abcam (Cambridge, UK)                                                            Cat\# ab62739; RRID:[AB_956300](https://scicrunch.org/resolver/AB_956300)                   Applications: WB; Immunofluoresce;Chromatin immunoprecipitation

  Antibody                          γH2AX                                         Abcam (Cambridge, UK)                                                            Cat\# ab81299; RRID:[AB_1640564](https://scicrunch.org/resolver/AB_1640564)                 Applications: WB

  Antibody                          p21                                           Santa Cruz Biotechnology                                                         Cat\# sc-6246; RRID:[AB_628073](https://scicrunch.org/resolver/AB_628073)                   Applications: WB

  Antibody                          MDM2                                          Santa Cruz Biotechnology                                                         Cat\# sc-965; RRID:[AB_627920](https://scicrunch.org/resolver/AB_627920)                    Applications: WB

  Antibody                          p-ATM (Ser1981)                               EMD Millipore                                                                    Cat\# 05--740; RRID:[AB_309954](https://scicrunch.org/resolver/AB_309954)                   Applications: WB

  Antibody                          H3K9ac                                        EMD Millipore                                                                    Cat\# 07--352; RRID:[AB_310544](https://scicrunch.org/resolver/AB_310544)                   Applications: WB; Chromatin immunoprecipitation

  Antibody                          p-S/T Q                                       Cell Signaling Technology (Beverly, MA)                                          Cat \#9607S; RRID:[AB_10889739](https://scicrunch.org/resolver/AB_10889739)                 Applications: WB

  Antibody                          cleaved caspase-3                             Cell Signaling Technology (Beverly, MA)                                          Cat \#9661; RRID:[AB_2341188](https://scicrunch.org/resolver/AB_2341188)                    Applications: WB

  Antibody                          HA                                            Sigma-Aldrich                                                                    Cat\# H3663; RRID:[AB_262051](https://scicrunch.org/resolver/AB_262051)                     Applications: WB

  Antibody                          Flag                                          Sigma-Aldrich                                                                    Cat\# F1804; RRID: [AB_262044](https://scicrunch.org/resolver/AB_262044)                    Applications: WB

  Antibody                          LC3B                                          Sigma-Aldrich                                                                    Cat\# L7543; RRID:[AB_796155](https://scicrunch.org/resolver/AB_796155)                     Applications: WB

  Transfected construct (human)     Flag-His-ATM wt                               Addgene (Cambridge, MA)                                                          Cat \#31985                                                                                 

  Transfected construct (human)     Flag-SIRT6                                    Addgene (Cambridge, MA)                                                          Cat \#13817                                                                                 

  Transfected construct (human)     Flag-His-ATM S1981A                           Addgene (Cambridge, MA)                                                          Cat \#32300                                                                                 

  Commercial assay or kit           Senescence beta- galactosidase staining Kit   Cell Signaling Technology (Beverly, MA)                                          Cat \#9860                                                                                  

  Commercial assay or kit           Lactate Colorimetric Assay Kit                BioVision                                                                        Cat \#K667-100                                                                              

  Commercial assay or kit           Click-iT EdU Alexa Fluor 488 Kit              Invitrogen                                                                       Cat \#C10425                                                                                

  Chemical compound, drug           Cycloheximide                                 Sigma-Aldrich                                                                    Cat \#66-81-9                                                                               

  Chemical compound, drug           MG-132                                        Sigma-Aldrich                                                                    Cat \#474787                                                                                

  Chemical compound, drug           Chloroquine                                   Sigma-Aldrich                                                                    Cat \#C6628                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

*Zmpste24-/-* mice and *Atm-/-* mice have been described previously ([@bib7]; [@bib59]). *Sirt6*-transgenic mice (*Sirt6*-tg) of C57BL/6J background were constructed by injecting cloned mSirt6 cDNA with CAG promoter into fertilized eggs. Primers for genotyping of *Sirt6* transgenic allele were as follows: forward: 5'-CTGGTTATTGTGCTGTCTCATCAT-3'; reverse: 5'-CCGTCTACGTTCTGGCTGAC-3'. *Atm-/-* mice were crossed to *Sirt6*-tg mice to get *Atm-/-;Sirt6*-tg mice. Chloroquine (CQ) experiments were conducted as described ([@bib65]). Briefly, 12-month-old wild-type C57BL/6J male mice, 2-month-old *Zmpste24-/-*, and *Atm-/-* male mice were administered with CQ (Sigma, St. Louis, MO) in 0.9% saline twice per week at 7 mg/kg body weight, and the control group was treated with saline alone. At least 8 weeks after treatment of CQ, mice were subjected to functional tests. Body weight and lifespan was recorded. The survival rate was analyzed using the Kaplan--Meier method and statistical comparison was performed using the Log-rank Test. Mice were housed and handled in the laboratory animal research center of Shenzhen University. All experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC). The protocols were approved by the Animal Welfare and Research Ethics Committee of Shenzhen University (Approval ID: 201412023).

*C. elegans* survival assay {#s4-2}
---------------------------

*C. elegans* nematode survival assay was performed according to standard protocols ([@bib34]). Briefly, wild-type and *atm-1* null nematodes (100 to 150 per group) synchronized to prefertile young adult stage were exposed to NGM plates containing the indicated dosage of CQ. After 1-day incubation, animals were transferred to fresh incubation plates without CQ for another 2 days. This procedure was repeated every 3 days. Nematodes that showed no response to gentle stimulation were recorded as dead. The survival data were analyzed using the Kaplan--Meier method and statistical comparison was performed using the Log-rank Test.

Cell lines {#s4-3}
----------

HEK293 (CRL-1573), HepG2 (HB-8065), and U2OS (HTB-96) cells were purchased from ATCC. Human skin fibroblasts HSFs (F2-S) and primary MEFs were prepared as described previously ([@bib44]). Immortalized *Atm-/-; p53-/-* and *Sirt6-/-* MEFs were provided as a kind gift from Dr. Yosef Shiloh (Tel Aviv University, Israel) and Dr. Raul Mostoslavsky (Massachusetts General Hospital Cancer center, USA), respectively. These cell lines were authenticated by short tandem repeat (STR) profile analysis and genotyping, and were mycoplasma free. Cells were cultured in Gibco DMEM (Life Technologies, USA) with 10% fetal bovine serum (FBS), 100 U/ml penicillin and streptomycin (P/S) at 37°C in 5% CO~2~ and atmospheric oxygen conditions. For CQ experiments, cells were maintained in the medium containing 1 μM chloroquine for 12 hr, and then grown in new fresh medium for 48 hr.

Plasmids {#s4-4}
--------

Human Flag-SIRT6, pcDNA3.1 Flag-ATM, Flag-ATM S1981A, and pcDNA3 human MDM2 were all purchased from Addgene (Cambridge, MA). Flag-SIRT6 with amino acid substitution mutations (S112A, S112D, K346R/K349R) were generated by PCR-based mutagenesis using pcDNA3-Flag-SIRT6 as a template and a QuikChange II site-directed mutagenesis kit (Agilent Technologies), following the manufacturer's instructions. Primer sequences for amino acid mutations of SIRT6 were as follows: SIRT6 S112A: (forward) 5\'-cgtccacgttctgggcgaccaggaagcgga-3\', (reverse) 5'-tccgcttcctggtcgcccagaacgtggacg-3'; SIRT6 S112D: (forward) 5\'-ccgtccacgttctggtcgaccaggaagcggag-3\', (reverse) 5\'-ctccgcttcctggtcgaccagaacgtggacgg-3\'; SIRT6 K346R: (forward) 5\'-ggccttcacccttctggggggtctgtg-3\', (reverse) 5\'-cacagaccccccagaagggtgaaggcc-3\'; SIRT6 K349R: (forward) 5\'-gccttggccctcacccttttggggggt-3\', (reverse) 5\'-accccccaaaagggtgagggccaaggc-3. HA-tagged human SIRT6 plasmid was amplified from the respective cDNAs and constructed into pKH3-HA vector. To express four truncated forms of SIRT6 protein, HA-SIRT6 plasmid as a template was constructed by PCR-based deletion.

Protein extraction and western blotting {#s4-5}
---------------------------------------

For whole cell protein extraction, cells were suspended in five volumes of suspension buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, protease inhibitor cocktail), and then five volumes of 2X SDS loading buffer were added and incubated at 98°C for 6 min. Mice tissues were homogenized with 1 ml of ice-cold tissue lysis buffer (25 mM TrisHCl, pH 7.5, 10 mM Na~3~VO~4~, 100 mM NaF, 50 mM Na~4~P~2~O~7~, 5 mM EGTA, 5 mM EDTA, 0.5% SDS, 1% NP-40, protease inhibitor cocktail). After homogenization and sonication, lysates were centrifuged at 16,000 g for 15 min. The clean supernatant was carefully transferred to new tubes. Protein concentrations were determined using a bicinchoninic acid (BCA) assay method (Pierce, Rockford, IL) and were normalized with lysis buffer for each sample. Samples were denatured in 1X SDS loading buffer by boiling at 98°C for 6 min. Proteins were separated by loading to SDS-polyacrylamide gels, and then were transferred to PVDF membrane (Millipore). The protein levels were determined by immunoblotting using respective antibodies. The ImageJ program was used for densitometric analysis of immunoblotting, and the quantification results were normalized to the loading control.

Antibodies {#s4-6}
----------

Rabbit anti-SIRT6 (ab62739), ATM (ab78), SIRT1 (ab12193), γH2AX (ab81299), RAP80 (ab52893), Kap-1 (ab10484), and p-KAP-1 (Ser824, ab70369) antibodies were obtained from Abcam (Cambridge, UK). Anti-lamin A/C (sc-20681), p21 (sc-6246), MDM2 (sc-965), and P53 (sc-6243) antibodies were purchased from Santa Cruz Biotechnology. Rabbit anti-γH2AX (05--636), p-ATM (Ser1981) (05--740), histone H3 (07--690), anti-H3K56ac (07--677), and H3K9ac (07--352) antibodies were sourced from EMD Millipore. Mouse anti-p-ATM (Ser1981) (\#5883), p-S/TQ (\#9607), ubiquitin (\#3936), and cleaved caspase-3 (\#9661) antibodies were purchased from Cell Signaling Technology (Beverly, MA). Mouse anti- HA, Flag, rabbit anti-LC3B, and P62 antibodies were obtained from Sigma-Aldrich. Anti-Nbs1 (NB100-143) antibody was purchased from Novus Biologicals. Mouse anti-actin, tubulin antibodies were obtained from Beyotime. Anti-pS112 SIRT6 monoclonal antibodies were prepared by Abmart generated from a specific phosphorylated peptide (peptide sequence CLRFVS~P~QNV).

Protein degradation assay {#s4-7}
-------------------------

HEK293 cells (WT and ATM-deficient cells) were transfected with Flag-SIRT6 alone or together with Mdm2. 48 hr later, the cells were treated with 50 μg/ml of cycloheximide (CHX, Sigma-Aldrich), a translation inhibitor. For endogenous SIRT6 protein degradation assay, *ATM* wild-type and null MEFs were grown in 6 cm plates, and were treated with 50 mg/ml CHX for indicated time points. Cells were collected and the protein levels were determined by western blotting, the subsequent quantification was performed with ImageJ software.

In vivo ubiquitination assay {#s4-8}
----------------------------

In vivo ubiquitination assay was performed by transfecting HEK293 cells in 6 cm dishes with 1 μg Myc-ubiquitin, 2 μg Flag-SIRT6 or its mutations, and/or 1 μg MDM2 vector. 48 hr after transfection, cells were lysed in the buffer (25 mM Tris-HCl pH 8.0, 250 mM NaCl, 10 mM Na~3~VO~4~, 1 mM EDTA, 10% glycerol, protease inhibitor cocktail, and 0.1 mM phenylmethylsulphonyl fluoride), and then incubated with Flag-M2 beads (Sigma-Aldrich) overnight at 4°C. Beads were washed with lysis buffer three times, bound proteins were eluted by adding 1.5 × SDS loading buffer. The ubiquitin levels were analyzed by immunoblotting.

In vitro kinase assay {#s4-9}
---------------------

HEK293T cells were transfected with 10 μg of FLAG-ATM and then treated with CPT. Activated ATM was immune-purified from the cell extracts with FLAG beads (Sigma, M8823). GST-SIRT6 or the S112A mutant was purified from bacteria. Kinase reactions were initiated by incubating purified ATM with GST-SIRT6 in the kinase buffer with or without 1 mM ATP for 120 min at 30°C. After reaction, proteins were blocked by SDS loading buffer. The membrane was then subjected to western blotting with antibodies against p-S/TQ.

Immunoprecipitation {#s4-10}
-------------------

Cells under indicated treatments were totally lysed in lysis buffer containing 20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM Na~3~VO~4~, 10% glycerol, 2 mM EDTA, protease inhibitor cocktail, and 0.1 mM phenylmethylsulphonyl fluoride. After sonication and centrifugation, the supernatant was collected and incubated with H3K9ac (Millipore, 2 μg/sample) overnight at 4°C with a gentle rotation. Protein A/G agarose (Pierce, 10 μl/sample) were added to the tubes and rotated at 4°C for 2 hr. Beads were precipitated by centrifugation at 1000 g for 15 s and washed three times with cold lysis buffer. The pellet was resuspended in 1.5 × SDS loading buffer and incubated at 98°C for 6 min. The supernatants were collected and used for western blotting.

GST pull-down assay {#s4-11}
-------------------

A series of GST fusion proteins of truncated ATM, which together spanned the full length of ATM, were constructed into pGEX4T-3 vector. For GST pull-down, bacterially expressed 6 × His tagged SIRT6 was separately incubated with various GST-ATM fragments in a buffer of 150 mM NaCl, 20 mM Tris-HCl \[pH 7.5\], 5 mM MgCl~2~, 0.2 mM EDTA, 10% glycerol, 0.2% NP-40, and protease inhibitors (Roche Complete). GST-fusion proteins were then precipitated by adding Glutathione Sepharose fast flow (GE Healthcare). After washing twice with TEN buffer (0.5% Nonidet P-40, 20 mM Tris-HCl \[pH 7.4\], 0.1 mM EDTA, and 300 mM NaCl), glutathione agarose beads were analyzed by western blotting and coomassie staining.

RNA interference and shRNA lentiviral infection {#s4-12}
-----------------------------------------------

Briefly, cells were transfected with small interfering RNAs (siRNAs) for 48 hr using Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer's instructions. The siRNAs targeting human *ATM*, *SIRT6*, and *HDM2* were purchased (GenePharma, China) with sequences as follows, si-*ATM*\#1: 5'-AAUGUCUUUGAGUAGUAUGUU-3' ([@bib87]); Si-*ATM*\#2: 5'-AAGCACCAGUCCAGUAUUGGC-3' ([@bib85]); si-*SIRT6*\#1: 5'-AAGAAUGUGCCAAGUGUAAGA-3'; si-*SIRT6*\#2: 5'-CCGGCTCTGCACCGTGGCTAA-3'; si*-HDM2*\#1: 5'-AACGCCACAAATCTGATAGTA-3'; si*-HDM2*\#2: 5'-AATGCCTCAATTCACATAGAT-3'. A scrambled siRNA sequence was used as control. Lentiviral shRNA constructs were generated in a pGLVH1 backbone (GenePharma, China), and virus was produced in HEK293 cells. To deplete ATM in HSF cells and SIRT6 in HepG2 cells, lentiviral infection was performed in the presence of 5 μg/ml polybrene. Two days later, the infected HSF cells or HepG2 cells were selected with 2 μg/ml puromycin. To downregulate sir-2.4 expression, the NL2099 worms were exposed to incubation plates containing HT115 bacteria with sir-2.4 RNAi vector.

CRISPR/Cas9-mediated genome editing {#s4-13}
-----------------------------------

Gene mutagenesis by the CRISPR/Cas9 system was conducted as described ([@bib61]). The following gRNAs targeting human *ATM*, *SIRT6* were constructed in pX459 vector (Addgene, \#48139). sg*ATM* F: 5'-CACCGATATGTGTTACGATGCCTTA-3', R: 5'- AAACTAAGGCATCGTAACACATATC-3'. HEK293 cells were transfected with pX459 or pX459-gRNA using Lipofetamine 3000 Transfection Reagent according to the manufacturer\'s instructions. After 2-day culture, cells were selected with 2 μg/ml puromycin, six colonies were picked and grown to establish stable cell lines. The targeted mutations were identified by western blotting, and PCR-based sequencing.

EdU (5-ethynyl-2'-deoxyuridine) incorporation assay {#s4-14}
---------------------------------------------------

EdU incorporation assays were conducted in HSF cells to estimate cell proliferation using the Click-iT EdU Alexa Fluor 488 Kit (Invitrogen, USA). HSF cells, infected by the respective lentiviruses containing shNC and sh*ATM*, were cultured in a six-well plate containing the coverslips in the presence of 10 μM EdU for 12 hr. Cells were fixed in 3.7% formaldehyde followed by 0.5% Triton X-100 permeabilization, and then stained with Alexa Fluor picolyl azide. Five random views were captured to calculate the positive staining rate for each group.

Growth curves and SA-β-gal assays {#s4-15}
---------------------------------

Cell population doublings were monitored using a Coulter Counter. SA-β-galactosidase assay in primary cells was performed using Senescence β-galactosidase staining Kit (\#9860, CST) according to the manufacturer\'s instructions. Five views were captured randomly to calculate the positive staining rate for each group.

RNA preparation and Real-Time qPCR {#s4-16}
----------------------------------

Total RNA was extracted from cells or mouse tissues using Trizol reagent RNAiso Plus (TaKaRa, Japan) following the phenol--chloroform extraction method. Purified total RNA was used to obtain cDNA using PrimeScript RT Master Mix (Takara, Japan) following this method: 37°C for 30 min, and 85°C for 5 s. The gene expression was analyzed with the CFX Connected Real-Time PCR Detection System (BioRad) with SYBR Ex Taq Premixes (Takara, Japan). Gene expression levels were normalized to actin.

Glucose tolerance test {#s4-17}
----------------------

Mice were fasted overnight (6 p.m. to 9 a.m.), and D-glucose (2.5 g/kg body weight) was administrated intraperitoneally. Blood glucose levels were determined from tail vein blood using a glucometer (Onetouch ultravue, Johnson, USA) at 0, 30, 60, 90, and 120 min after D-glucose injection.

Insulin tolerance test {#s4-18}
----------------------

Mice were fasted for 6 hr (8 a.m. to 2 p.m.), and recombinant human insulin (0.75 U/kg body weight) was administered intraperitoneally. Blood glucose levels were determined in tail vein blood using a glucometer (Onetouch ultravue, Johnson) at 0, 30, 60, 90, and 120 min after insulin injection.

Lactate assay {#s4-19}
-------------

Mouse serum was five-fold diluted, and lactate concentration was determined with the Lactate Colorimetric Assay Kit (BioVision).

Endurance running test {#s4-20}
----------------------

*Zmpste24-/-* mice were treated for 8 weeks with chloroquine or saline before running on a Rota-Rod Treadmill (YLS-4C, Jinan Yiyan Scientific Research Company, Shandong, China) to test the effect of chloroquine on fatigue resistance. Mice were placed on the rotating lane, and the speed was gradually increased to 10 r/min. When mice were exhausted and safely dropped from the rotating lane, the time latency to fall was automatically recorded.

Metabolite analysis {#s4-21}
-------------------

Wild-type and *ATM* KO cells were grown in normal medium for 24 hr, and methanol-fixed cell pellets were analyzed by a two liquid chromatography-tandem mass spectrometry (LC-MS) method as described ([@bib50]).

Immunofluorescence microscopy {#s4-22}
-----------------------------

The cells were fixed using 4% paraformaldehyde at room temperature for 15 min, permeabilized by 0.5% Triton X-100 at room temperature for 10 min, blocked using 10% FBS/PBS, and then incubated with primary antibodies diluted in PBS containing 2% BSA overnight at 4°C. The primary antibodies were detected using an Alexa-488-conjugated anti-mouse secondary antibody (Invitrogen). The nuclei were stained using DAPI in anti-fade mounting medium. Images were captured using a Zeiss LSM880 confocal/multiphoton microscope.

ChIP assay {#s4-23}
----------

Cells were fixed in 1% formaldehyde for 10 min at room temperature. The crosslinking reaction was quenched with 0.125 M glycine. After washing with PBS, cells were lysed with lysis buffer (50 mM Tris·HCl pH 8.0, 2 mM EDTA, 15 mM NaCl, 1% SDS, 0.5% deoxycholate, protease inhibitor cocktail, 1 mM PMSF), followed by sonication and centrifugation. The supernatant was collected and precleared in dilution buffer (50 mM Tris-HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100) with protein A/G Sepharose and pre-treated salmon DNA. The precleared samples were incubated overnight with H3K9ac antibody (2 μg/sample, Millipore) or appropriate control IgGs (Santa Cruz), and protein A/G Sepharose (Invitrogen). After washing sequentially with a series of buffers, the beads were heated at 65°C to reverse the crosslink. DNA fragments were purified and analyzed. Real-time PCR was performed with primers as described ([@bib86]):

LDHB-ChIP-5': AGAGAGAGCGCTTCGCATAG

LDHB-ChIP-3': GGCTGGATGAGACAAAGAGC

ALDOC-ChIP-5': AAGTGGGGCACTGTTAGGTG

ALDOC-ChIP-3': GTTGGGGATTAAGCCTGGTT

PFKM-ChIP-5': TTAAGACAAAGCCTGGCACA

PFKM-ChIP-3': CAACCACAGCAATTGACCAC

LDHA-ChIP-5': AGGGGGTGTGTGAAAACAAG

LDHA-ChIP-3': ATGGCTTGCCAGCTTACATC

LDHA-ChIP-1Kb-5': TGCAAGACAAGTGTCCCTGT

LDHA-ChIP-1Kb-3': GAGGGAATGAAGCTCACAGC

Statistical analysis {#s4-24}
--------------------

Statistical analyses were conducted using two-tailed Student\'s *t*-test between two groups. All data are presented as mean ± S.D. or mean ± S.E.M. as indicated, and a *p* value \< 0.05 was considered statistically significant.
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Sequencing data have been deposited in GEO under accession code GSE109280.

The following dataset was generated:

Qian MLiu B2018Boosting ATM activity alleviates ageing and extends lifespan in a mouse model of progeria.<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109280>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE109280).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Boosting ATM Activity Promotes Longevity in Nematodes and Mice\" for consideration by *eLife*. Your article has been favorably evaluated by Jessica Tyler (Senior Editor) and three reviewers, one of whom, Matt Kaeberlein (Reviewer \#1), is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

All of the reviewers recognized the important and novel insights provided in this manuscript linking ATM, SIRT6, and longevity, but that there are some key revisions that need to be made before publication. In particular, the effects reported from CQ treatment are quite interesting, but could be due to targets other than ATM. It would greatly strengthen the manuscript to show genetically that ATM activation/overexpression recapitulates at least some of the reported phenotypes. This may not be feasible in mice, but is doable in worms or cells.

Several additional controls are needed to demonstrate phosphorylation of SIRT6 by ATM, as noted by reviewer \#2.

There is some question as to whether the increases in lifespan observed in the manuscript are due to improved DNA damage response or to metabolic changes. In the absence of additional data addressing these two possibilities, the authors are encouraged to interpret their data in a more agnostic way and consider both models. This should be done both in the text and in a revised model figure.

Use of different cell lines for different experiments is confusing and detracts from confidence in the results. For example, why were MEFs used for senescence but HSFs were used for other assays, and HepG2 for even other assays. Optimally, most or all of the experiments would be done in a single consistent cell line.

There are numerous errors in grammar and data presentation throughout the manuscript. Several of these are listed below, and the authors should take much more care in preparing the revised version of their manuscript. Careful proofreading for English sentence structure and phrasing is also important.

Essential revisions:

1\) Title: The title is a bit misleading and implies that the study shows that boosting ATM activity promotes longevity in wild type mice. I don\'t think it\'s necessary for the authors to show lifespan extension in wild type mice for publication, but their title and Abstract need to be changed so that it is clear that the longevity effects in mice are limited to short-lived mouse models of disease.

2\) The authors should explain why the replicative senescence experiments were done in MEFs rather than HSFs and perhaps repeat these experiments in HSFs. Did the experiment not work in HSFs? Showing that CQ can extend replicative lifespan in HSFs would seem to be more relevant than MEFs. I also worry that the replicative capacity of the MEFs here is so short. Was this done under atmospheric oxygen conditions and, if so, it needs to be repeated under lower oxygen.

3\) I found the worm experiments to be the least convincing part of the manuscript. Drug studies in worms are complicated by potential effects on the bacterial food, which I don\'t think was addressed here. There is no biochemical evidence that CQ gets into worms or modifies activity of the worm ATM homolog. There is no evidence that the worm ATM homolog phosphorylates the worm SIRT6 homolog. Again, the story sticks together with the model, but there are a lot of apparent assumptions that need to be made here. I realize the tools aren\'t available to do some of this, but you could show that transgenic overexpression of ATM is sufficient to have effects similar to CQ and increase lifespan in a sir-2.4-dependent manner.

4\) The part of the paper dealing with phosphorylation of SIRT6 by ATM is novel and interesting, but needs some additional controls.

a\) Figure 3D shows that both SIRT6 and ATM are in the nucleus (not surprisingly), but it is hard to judge whether they are co-localized. Ether a higher resolution confocal microscope is needed, or the figure can be removed.

b\) Figure 4C, D: the gel does not show any difference between SIRT6 WT and S112D, yet quantification on the right shows very large effect. The authors need to provide a gel that corresponds to the quantification.

c\) It is important to knock-in the SIRT6 S112 mutations in a cell line and perform RNAseq (or qRT-PCR on glycolytic genes) to prove that the mutation indeed affects SIRT6 regulated genes.

5\) In Figure 2---figure supplement 1C, Figure 2h and Figure 2---figure supplement 2B, there were not have enough biological replicates.

10.7554/eLife.34836.030

Author response

> Essential revisions:
>
> 1\) Title: The title is a bit misleading and implies that the study shows that boosting ATM activity promotes longevity in wild type mice. I don\'t think it\'s necessary for the authors to show lifespan extension in wild type mice for publication, but their title and Abstract need to be changed so that it is clear that the longevity effects in mice are limited to short-lived mouse models of disease.

We appreciate the reviewers' suggestion. We have now removed related data in the revised manuscript and corresponding figures as requested. We will investigate the effect of CQ on physiological ageing in an independent project. As suggested, we changed the title to "Boosting ATM activity alleviates ageing and extends lifespan in a mouse model of progeria". Accordingly, the Abstract was re-written; the figure panels were reorganized (see revised Figure 5 and Figure 5---figure supplement 1).

> 2\) The authors should explain why the replicative senescence experiments were done in MEFs rather than HSFs and perhaps repeat these experiments in HSFs. Did the experiment not work in HSFs? Showing that CQ can extend replicative lifespan in HSFs would seem to be more relevant than MEFs. I also worry that the replicative capacity of the MEFs here is so short. Was this done under atmospheric oxygen conditions and, if so, it needs to be repeated under lower oxygen.

We thank the reviewers for their comments and suggestions. We performed the requested experiments in HSFs and showed consistent result that CQ extends replicative lifespan (see revised Figure 1J). We did notice that MEFs have a very limited growth capacity and could be spontaneously immortalized at a low frequency as a result of prolonged passaging (Sun and Taneja, 2007). Indeed, to demonstrate that ATM declines with age and senescence, we utilized two cell lines, HSFs and MEFs (revised Figure 1A and 1B). We showed that activating ATM via CQ retards senescence in both HSFs and MEFs (revised Figure 1H, 1I and Figure 1---figure supplement 2D-E). Under atmospheric oxygen conditions, normal primary MEFs undergo 10 ± 2 population doublingsin vitro, and then rapidly enter a slow growth status that has been described as replicative senescence (Blasco et al., 1997; Rittling, 1996; Todaro and Green, 1963). As suggested, we examined the effect of CQ on senescence of MEFS at physiological (3%) oxygen level. Compared with 20% O~2~, MEFs in 3% O~2~ exhibit no remarkable signs of senescence even reaching passage 9 (see Author Response Image 1), which is indeed consistent with existing literature (Parrinello et al., 2003). As indicated, the cultures in 3% O~2~ can reach more than 60 population doublings without any senescence phenotypes. In current project, to address that CQ treatment alleviates senescence by activating ATM and promoting clearance of DNA damage, we think it is appropriate to examine the replicative lifespan of MEFs under standard culture conditions, which exhibit shortened lifespan predominantly triggered by DNA damage accumulation. Thus, the Author Response Image 1 was not included in the revised manuscript.

![Physiological (3%) oxygen condition is inappropriate for MEFs culture to assess the replicative lifespan-extending effect of CQ.\
(**a**) MEFs at passage 1 were cultured in 20% O~2~ (black) or 3% O~2~ (grey) with treatment of 1 μM CQ (circles) or DMSO (squares), and cell number was determined at each passage. \*\*\**P* \< 0.01. (**b**) Quantitative RT-PCR analysis of mRNA levels of *p16* and *p21* genes in different passages of MEFs with or without treatment of CQ in 20% O~2~ or 3% O~2~. \*\*\**P* \< 0.001. 'ns' indicates no significant difference. (**c**) Representative images showing morphology of MEFs under the indicated culture conditions with or without CQ treatment. (**d**) Quantification of SA-β-Gal-positive cells under indicated culture conditions. Data represent the means ± SEM. \*\*\**P* \< 0.001; 'ns' indicates no significant difference.](elife-34836-resp-fig1){#respfig1}

> 3\) I found the worm experiments to be the least convincing part of the manuscript. Drug studies in worms are complicated by potential effects on the bacterial food, which I don\'t think was addressed here. There is no biochemical evidence that CQ gets into worms or modifies activity of the worm ATM homolog. There is no evidence that the worm ATM homolog phosphorylates the worm SIRT6 homolog. Again, the story sticks together with the model, but there are a lot of apparent assumptions that need to be made here. I realize the tools aren\'t available to do some of this, but you could show that transgenic overexpression of ATM is sufficient to have effects similar to CQ and increase lifespan in a sir-2.4-dependent manner.

We agree with the reviewers that drug studies in worms are complicated and there is lack of solid evidence to support that worm ATM could phosphorylate *sir2.4*. In this study, we performed CQ treatment on N2, *atm-1* KO and *sir2.4*-depleted nematodes, showing that CQ extends lifespan of N2 worms, but not that of *atm-1* KO or *sir2.4*-depleted worms. The parallel treatment largely precludes potential effects of CQ on the bacterial food. To further strengthen the conclusion, as the reviewers suggested, we attempted to investigate the lifespan-extending effect of extra copies of *ATM-1* in worms. Since the endogenous *AMT-1* gene promoter is unknown and a 2 kb region at the upstream of *ATM-1* ORF did not work in our test, we constructed a large plasmid pPD95_75 with GFP-tagged full-length *ATM-1* (\~7kbp) under the promoter of *sir2.4* (Chiang et al., 2012). The results indeed showed significant effect on lifespan extension (see Author Response Image 2). Of note, the heterozygous instead of homozygous status of a SNP, albeit both enhance the transcription of ATM, is associated with longevity in Chinese and Italian populations (Chen et al., 2010; Piaceri et al., 2013). However, though GFP tag was detected, we were unable to determine the amount of ectopic *ATM-1* in transgenic worms. In future study, it would be worthwhile to evaluate how many extra copies of Atm could maximally promote longevity in model organisms.

For dosage-dependent studies, while both 10 μM and 1 μM of CQ activate ATM, only 1 μM of CQ was suitably applied in the studies, which promotes longevity in HSFs, *Zmpste24-/-* mice, and nematodes, but exhibits little effect in *ATM*-depleted mice and worms. Perhaps it is an important facet of the amount of ATM for pro-longevity, requiring further study. We discussed this in the revised manuscript.

*C. elegans* with conserved DDR mechanism seems to be as a promising model for the investigation of DNA repair (Jones et al., 2012; Lemmens and Tijsterman, 2011). *ATM-1* in *C. elegans*, the homolog of mammalian ATM, is known to function in DDR and DSB repair, and its activity and functional interactions are conserved between worms and humans (Lee et al., 2010; Lemmens and Tijsterman, 2011). Similar to A-T patients and *Atm-/-* mice, loss-of-function of ATM-1 results in genomic instability and shortened lifespan (Fang et al., 2016; Jones et al., 2012). To test the lifespan-extending effect of ATM at organismal level, we employed *Zmpste24-/-* mice with reduced ATM and DNA repair capacity*, ATM-/-* mice and wild-type nematodes for CQ administration. The results showed that CQ improves SIRT6 protein level and extends the lifespan of *Zmpste24-/-* mice and N2 worms, but not that of *Atm-/-* mice and *ATM-1* KO worms. Moreover, the cellular data indicated that CQ promotes replicative lifespan of HSFs in an ATM-dependent manner. Biochemical studies revealed that ATM phosphorylates SIRT6 at the conserved Ser112 residue, blocking MDM2-mediated proteasomal degradation. Generally, based on these studies, we rationally believe that our current data is adequate to support a pro-longevity role of ATM.

![Lifespan analysis for worms overexpressing ATM-1.\
(**a**) The strategy for constructing ATM-1 overexpressing plasmid with GFP-tag. (**b**) Representative images showing the detectable GFP expression in worms. (**c**) Survival analysis of worm line expressing GFP-ATM-1. \**P* \< 0.05.](elife-34836-resp-fig2){#respfig2}

> 4\) The part of the paper dealing with phosphorylation of SIRT6 by ATM is novel and interesting, but needs some additional controls.
>
> a\) Figure 3D shows that both SIRT6 and ATM are in the nucleus (not surprisingly), but it is hard to judge whether they are co-localized. Ether a higher resolution confocal microscope is needed, or the figure can be removed.

We thank the reviewers for the suggestion. SIRT6 is a nuclear NAD^+^-dependent deacetylase; ATM kinase is highly enriched in nuclei and also detectable in cytoplasm (Gately et al., 1998), which are consistent with our immunostaining result using SIRT6 and ATM antibodies. We have now presented high resolution confocal images, clearly showing intracellular punctate co-localization of SIRT6 and ATM (revised Figure 3D).

> b\) Figure 4C, D: the gel does not show any difference between SIRT6 WT and S112D, yet quantification on the right shows very large effect. The authors need to provide a gel that corresponds to the quantification.

We are thankful to the reviewers for their careful reading. We now presented new Western blots in revised Figure 4C, showing more clearly that S112D significantly retards SIRT6 degradation.

> c\) It is important to knock-in the SIRT6 S112 mutations in a cell line and perform RNAseq (or qRT-PCR on glycolytic genes) to prove that the mutation indeed affects SIRT6 regulated genes.

We appreciate for the reviewers' insightful comments. Deficiency of *ATM* or *SIRT6* enhances the expression of glycolytic genes, whereas re-expressed SIRT6 in *ATM*-depleted HepG2 rescues the increase of glycolysis. ATM directly interacts with SIRT6 and phosphorylates it at Ser112. It is important to check the inhibitory effect of SIRT6 S112 mutations on glycolytic gene expression. Unfortunately, we failed to knock-in the SIRT6 S112 mutations in HepG2 by CRISPR-Cas9 system. Instead, to address this issue, we have now provided additional evidence from a practical approach. We utilized *SIRT6*-depleted HepG2 cells (revised Figure 3---figure supplement 1L), generated by shRNA lentiviral system (see Materials and methods) and re-constituted with SIRT6 WT, S112A and S112D. As shown in revised Figure 3M, the qRT-PCR data demonstrated that SIRT6 S112D exhibits more inhibitory effect on glycolytic gene expression than S112A. In addition, sub-cellular fractionation experiment showed that S112D enhances the chromatin-binding capacity of SIRT6, whereas S112A abrogated it (see revised Figure 3N). Our data suggest that SIRT6 S112A loses the regulation on targeted genes due to reduced chromatin-binding affinity and protein stability. Additional data indicate that ATM depletion or S112A mutation promotes SIRT6 degradation via MDM2-mediated proteasomal pathway.

> 5\) In Figure 2---figure supplement 1C, Figure 2h and Figure 2---figure supplement 2B, there were not have enough biological replicates.

According to the reviewer's suggestion, we have done these experiments with more repeats (n = 6 for each group) and did statistical analysis as shown in revised Figure 2---figure supplement 1C, Figure 2H and Figure 2---figure supplement 2B. The details have been included in revised figure legends.

[^1]: These authors contributed equally to this work.
